Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Baseline characteristics of the study populationVariableTotal(n = 145)Subgroup with guideline assessment (n = 117)Age, years80.4 ± 9.282.3 ± 7.9 Minimum5559 Maximum9797Sex, n (%) Female103 (71.0)92 (78.6) Male42 (29.0)25 (21.4)Comorbidities, n (%) Hypertension95 (65.5)82 (70.1) Visual impairment4 (2.8)4 (3.4) Cardiovascular disease65 (44.8)55 (47.0) Parkinson’s disease7 (4.8)4 (3.4) Dementia28 (19.3)27 (23.1) Diabetes mellitus30 (20.7)27 (23.1) Hyperlipidemia60 (41.4)51 (43.6) Chronic obstructive pulmonary disease22 (15.2)19 (16.2) Malignancy21 (14.5)17 (14.5) Prior osteoporosis diagnosis41 (28.3)41 (35.0)FRAX® risk category, n (%) Low17 (11.7)1 (0.9) Moderate16 (11.0)4 (3.4) High28 (19.3)28 (23.9) Very high84 (57.9)84 (71.8)Vitamin D and/or calcium supplementation, n (%)73 (50.3)69 (59.0)Fracture type (ICD-10), n (%) Femoral neck fracture (S72.0)74 (51.0)61 (52.1) Pertrochanteric fracture (S72.1)51 (35.2)40 (34.2) Subtrochanteric fracture (S72.2)1 (0.7)1 (0.9) Femoral shaft fracture (S72.3)15 (10.3)13 (11.1) Distal femur fracture (S72.4)4 (2.8)2 (1.7)Values are presented as mean ± standard deviation or number (percentage)

Source: Study population. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study

Source: Article title.

In this prospective observational study, 145 patients aged ≥ 55 years admitted with femoral neck, per: and subtrochanteric, femoral shaft and distal femur fractures to a tertiary academic trauma center between April and June 2025 were included.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study

Observational study · Archives of Orthopaedic and Trauma Surgery · 2026

Original publication title

Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study

Lukas Böck; Katharina Kerschan-Schindl; Martin Frossard; Stefan Hajdu; Richard Crevenna; Martina Anditsch; Gunar Stemer; Anna Antoni

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Patients presenting with femoral fractures demonstrate a substantial gap in guideline-concordant osteoporosis therapy and a high prevalence of medications associated with increased fall and fracture risk. These findings highlight important opportunities for systematic primary and secondary fracture prevention and structured medication review.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Hip fractures are a major complication of osteoporosis and are associated with high morbidity, mortality, and costs. Despite clear guideline recommendations, pharmacological osteoporosis treatment remains underutilized. In addition, medications that increase fall and fracture risk further contribute to fracture occurrence. The aim of this study was to assess guideline concordance of osteoporosis therapy and to quantify the prevalence of medications associated with increased fall and fracture risk prior to the fracture in patients admitted with femoral fractures.

Source: Introduction

Abstract: What methods does the paper describe?

In this prospective observational study, 145 patients aged ≥ 55 years admitted with femoral neck, per: and subtrochanteric, femoral shaft and distal femur fractures to a tertiary academic trauma center between April and June 2025 were included. Pre-admission medication was assessed using structured medication reconciliation. Guideline concordance of pre-fracture osteoporosis therapy was evaluated according to the current Austrian osteoporosis guideline (Dimai et al., 2024). Fall-risk-increasing drugs (FRIDs) were identified using the STOPPFall criteria, and fracture-associated medications were recorded based on Austrian osteoporosis guideline-defined drug classes.

Source: Materials and methods

Abstract: Results

Among 145 included patients (mean age 80.4 years; 71% female), 117 (81%) met criteria for pharmacological osteoporosis treatment prior to the fracture, defined by a preexisting osteoporosis diagnosis or a 10-year fracture risk above the treatment intervention threshold using the FRAX® calculator. Only 9 (7.7%) of these patients were treated in accordance with guideline recommendations. A treatment gap was observed in 78.6% of therapy-eligible patients. At least one FRID was prescribed in 70% of patients, and 57% received at least one medication associated with increased fracture risk.

Source: Results

Abstract: Conclusions

Patients presenting with femoral fractures demonstrate a substantial gap in guideline-concordant osteoporosis therapy and a high prevalence of medications associated with increased fall and fracture risk. These findings highlight important opportunities for systematic primary and secondary fracture prevention and structured medication review.

Source: Conclusions
Authors’ abstract

Introduction

Hip fractures are a major complication of osteoporosis and are associated with high morbidity, mortality, and costs. Despite clear guideline recommendations, pharmacological osteoporosis treatment remains underutilized. In addition, medications that increase fall and fracture risk further contribute to fracture occurrence. The aim of this study was to assess guideline concordance of osteoporosis therapy and to quantify the prevalence of medications associated with increased fall and fracture risk prior to the fracture in patients admitted with femoral fractures.

Materials and methods

In this prospective observational study, 145 patients aged ≥ 55 years admitted with femoral neck, per: and subtrochanteric, femoral shaft and distal femur fractures to a tertiary academic trauma center between April and June 2025 were included. Pre-admission medication was assessed using structured medication reconciliation. Guideline concordance of pre-fracture osteoporosis therapy was evaluated according to the current Austrian osteoporosis guideline (Dimai et al., 2024). Fall-risk-increasing drugs (FRIDs) were identified using the STOPPFall criteria, and fracture-associated medications were recorded based on Austrian osteoporosis guideline-defined drug classes.

Results

Among 145 included patients (mean age 80.4 years; 71% female), 117 (81%) met criteria for pharmacological osteoporosis treatment prior to the fracture, defined by a preexisting osteoporosis diagnosis or a 10-year fracture risk above the treatment intervention threshold using the FRAX® calculator. Only 9 (7.7%) of these patients were treated in accordance with guideline recommendations. A treatment gap was observed in 78.6% of therapy-eligible patients. At least one FRID was prescribed in 70% of patients, and 57% received at least one medication associated with increased fracture risk.

Conclusions

Patients presenting with femoral fractures demonstrate a substantial gap in guideline-concordant osteoporosis therapy and a high prevalence of medications associated with increased fall and fracture risk. These findings highlight important opportunities for systematic primary and secondary fracture prevention and structured medication review.

Publication and source details

Original title: Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study

Lukas Böck; Katharina Kerschan-Schindl; Martin Frossard; Stefan Hajdu; Richard Crevenna; Martina Anditsch; Gunar Stemer; Anna Antoni

Archives of Orthopaedic and Trauma Surgery · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Medical University of Vienna

Open access funding provided by Medical University of Vienna.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:10:58.238140+00:00

DOI: 10.1007/s00402-026-06401-5 · PMC13331906